In these conditions, CD109 could contribute to immune dysfunction by promoting a suppressive tumor microenvironment, characterized by impaired cytotoxic lymphocyte activity, cytokine imbalances, and chronic inflammation. The gene discussed is CD109; the disease is neoplasm.